How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options.

Zerdes, Ioannis; Tolia, Maria; Nikolaou, Michail; Tsoukalas, Nikolaos; Velentza, Louloudenia; Hajiioannou, Jiannis; Mitsis, Michail; Kyrgias, George

Zerdes, Ioannis; Tolia, Maria; Nikolaou, Michail; Tsoukalas, Nikolaos; Velentza, Louloudenia; Hajiioannou, Jiannis; Mitsis, Michail; Kyrgias, George.

Affiliation

Zerdes I; University of Ioannina, School of Health Sciences, Faculty of Medicine, Ioannina, Greece.

J BUON ; 22(4): 1073-1080, 2017.

Article in En | MEDLINE | ID: mdl-28952230

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Dermatomyositis/diagnosis; Dermatomyositis/drug therapy; Paraneoplastic Syndromes/diagnosis; Paraneoplastic Syndromes/drug therapy; Clinical Trials as Topic; Humans; Neoplasms/diagnosis; Neoplasms/drug therapy; Prednisone/therapeutic use; Randomized Controlled Trials as Topic; Risk Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Paraneoplastic Syndromes / Dermatomyositis / Anti-Inflammatory Agents Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: Greece

Search on Google

XML

PubMed Links